PSTV
HEALTHCAREPlus Therapeutics Inc
$6.00-0.22 (-3.54%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PSTV Today?
No stock-specific AI insight has been generated for PSTV yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.90$23.50
$6.00
Fundamentals
Market Cap$41M
P/E Ratio—
EPS$-7.25
Dividend Yield—
Dividend / Share—
ROE-5.2%
Profit Margin—
Debt / Equity—
Trading
Volume176K
Avg Volume (10D)—
Shares Outstanding6.9M
PSTV News
20 articles- Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal MetastasesYahoo Finance·May 8, 2026
- OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 8, 2026
- Plus Therapeutics Receives Medicare Enrollment Approval for CNSide DiagnosticYahoo Finance·May 7, 2026
- Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerYahoo Finance·Apr 28, 2026
- Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™Yahoo Finance·Apr 23, 2026
- Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 22, 2026
- Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementYahoo Finance·Apr 21, 2026
- Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial ExecutionYahoo Finance·Apr 15, 2026
- Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical PipelineYahoo Finance·Apr 9, 2026
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant GliomasYahoo Finance·Apr 8, 2026
- D. Boral Capital Downgrades Plus Therapeutics (PSTV) to HoldYahoo Finance·Apr 7, 2026
- Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial AdoptionYahoo Finance·Apr 7, 2026
- Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered LivesYahoo Finance·Apr 2, 2026
- Plus Therapeutics Announces Reverse Stock SplitYahoo Finance·Mar 31, 2026
- Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of DirectorsYahoo Finance·Mar 26, 2026
- Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%Yahoo Finance·Mar 19, 2026
- Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4Yahoo Finance·Mar 12, 2026
- Plus: Q4 Earnings SnapshotYahoo Finance·Mar 12, 2026
- Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 12, 2026
- Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial RolloutYahoo Finance·Mar 12, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$6.22
Day High$0.00
Day Low$0.00
52 Week High$23.50
52 Week Low$2.90
52-Week Range
$2.90$23.50
$6.00
Fundamentals
Market Cap$41M
P/E Ratio—
EPS$-7.25
Dividend Yield—
Dividend / Share—
ROE-5.2%
Profit Margin—
Debt / Equity—
Trading
Volume176K
Avg Volume (10D)—
Shares Outstanding6.9M
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing, and commercialization of treatments for patients with cancer and other diseases. The company is headquartered in Austin, Texas.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—